

Statement of Standalone Unaudited Financial Results for the Quarter and Six Months Ended on 30/09/2016
PART I

(Rs. in Lakh, except per share data)

Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	Year to date Current Period ended	Year to date figures for the Previous year ended	Previous Year ended
		30/09/2016	30/06/2016	30/09/2015	30/09/2016	30/09/2015	31/03/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
(a)	Net Sales/Income from Operations	2861.30	2223.21	2512.57	5084.51	4696.88	9294.13
(b)	Other Operating Income	7.81	7.56	5.25	15.37	42.99	64.37
	Total income from Operations (net of Excise)	2869.11	2230.77	2517.82	5099.88	4739.87	9358.50
2	Expenses						
(a)	Cost of Materials Consumed	157.27	163.11	180.92	320.38	354.87	670.25
(b)	Purchase of Stock-in-trade	703.06	380.65	712.71	1083.71	1197.17	2218.55
(c)	Changes in inventories of Finished Goods, Work-in Progress and Stock-in-trade	19.69	179.58	-116.62	199.27	-108.33	-120.80
(d)	Employee benefit expenses	558.84	616.61	509.33	1175.45	1058.32	2149.02
(e)	Depreciation and Amortisation Expense	44.65	44.11	46.73	88.76	92.48	199.17
(f)	other expenses	736.59	615.92	706.46	1352.51	1351.83	2795.56
	Total Expenses	2220.10	1999.98	2039.53	4220.08	3946.34	7911.79
3	Profit from operations before other income, finance costs and exceptional items (1-2)	649.01	230.79	478.29	879.80	793.53	1446.71
4	other income	61.97	60.20	59.54	122.17	118.44	273.40
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	710.98	290.99	537.83	1001.97	911.97	1720.11
6	Finance Costs	11.15	8.67	7.34	19.82	17.73	37.81
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	699.83	282.32	530.49	982.15	894.24	1682.30
8	Exceptional Items	0.75	12.15	0.10	12.90	0.10	0.54
9	Profit from ordinary activities before tax (7 + 8)	700.58	294.47	530.59	995.05	894.34	1682.83
10	Tax Expense	197.58	99.52	187.66	297.10	296.06	604.93
11	Net Profit from ordinary activities after tax (9 - 10)	503.00	194.95	342.93	697.95	598.28	1077.90
12	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11 + 12)	503.00	194.95	342.93	697.95	598.28	1077.90
14	Paid-up equity share capital - F.V. Rs.10/-	464.93	464.93	464.93	464.93	464.93	464.93
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	3553.94
16 (i)	Earnings Per Share (before extraordinary items) - F.V. Rs.10/-						
	Basic and diluted	10.82	4.19	7.38	15.01	12.87	23.18
(ii)	Earnings Per Share (after extraordinary items) - F.V. Rs.10/-						
	Basic and diluted	10.82	4.19	7.38	15.01	12.87	23.18

For Jenburkt Pharmaceuticals Ltd.



(Ashish U. Bhuta)
Chairman and Managing Director.

Place : Mumbai

Date : 22nd Oct, 2016


Science hai toh Hope hai

Hope hai toh Health hai

Health hai toh Happiness hai



Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127


Standalone Statement of Assets and Liabilities			
Particulars		As at 30/09/2016 (Rs.in lacs)	As at 31/03/2016 (Rs.in lacs)
A	EQUITY AND LIABILITIES		
1	Share Holders' Fund		
	(a) Share Capital	464.93	464.93
	(b) Reserves & Surplus	4254.78	3553.94
	(c) Money received against share warrants	0.00	0.00
	Sub - Total - Share Holders' Fund	4719.71	4018.87
2	Share Application Money Pending Allotment	0.00	0.00
3	Minority Interest	0.00	0.00
4	Non Current Liabilities		
	(a) Long Term Borrowings	24.37	24.61
	(b) Deferred Tax Liability (Net)	57.73	63.14
	(c) Other Long Term Liabilities	289.91	287.91
	(d) Long Term Provisions	0.00	0.00
	Sub -Total - Non Current Liabilities	372.01	375.66
5	Current Liabilities		
	(a) Short Term Borrowings	204.91	517.31
	(b) Trade Payables	600.06	330.26
	(c) Other Current Liabilities	478.87	467.46
	(d) Short Term Provisions	34.39	93.35
	Sub -Total - Current Liabilities	1318.23	1408.38
	Total - Equity & Liabilities	6409.95	5802.91
B	ASSETS		
1	Non Current Assets		
	(a) Fixed Assets	1125.90	1210.65
	(b) Goodwill on Consolidation	0.00	0.00
	(c) Non Current Investments	86.33	61.33
	(d) Deferred Tax Assets (Net)	0.00	0.00
	(e) Long Term Loans & Advances	0.00	0.00
	(f) Other Non Current assets	0.00	0.00
	Sub-Total - Non Current Assets	1212.23	1271.98
2	Current Assets		
	(a) Current Investments	0.00	0.00
	(b) Inventories	622.21	823.84
	(c) Trade Receivables	779.81	577.66
	(d) Cash & Cash Equivalents	3627.69	2963.53
	(e) Short Term Loans & Advances	74.19	52.69
	(f) Other Current Assets	93.82	113.20
	Sub - Total - Current Assets	5197.72	4530.93
	Total - Assets	6409.95	5802.91

Notes:

- 1 The above unaudited financial results for the half year ended on 30.09.2016 were taken on record by the audit committee and board of directors of the company at their respective meetings held on 22.10.2016.
- 2 The company is dealing exclusively in pharmaceuticals business segment, hence segmentwise reporting is not applicable.
- 3 The figures of previous year have been reclassified / regrouped / rearranged wherever necessary.

Place : Mumbai
Date : 22nd October, 2016

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(Ashish U. Bhuta)
Chairman and Managing Director.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 



Dilip. L. Arora

B.Com (Hons.), F.C.A

D.L.ARORA & Co.
CHARTERED ACCOUNTANTS

**LIMITED REVIEW REPORT TO THE BOARD OF DIRECTORS OF JENBURKT
PHARMACEUTICALS LIMITED**

TO
THE BOARD OF DIRECTORS,
JENBURKT PHARMACEUTICALS LIMITED,
Mumbai

We have reviewed the accompanying statement of unaudited statement of financial result of **Jenburkt Pharmaceuticals Limited** ("the company"), for the quarter ended on September 30, 2016 (" the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016 .This statement is the responsibility of the Company's Management and has been approved by the Board of Directors . Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 , "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly , we do not express an audit opinion .

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai.
Date: 22/10/2016

E:\My Documents - 1\Jenburkt\Limited review report\sep/2016.



For D.L.Arora & Co.
Chartered Accountants
FRN.: 100545W

Dilip Arora
Proprietor
M. No.: 036152